NewTimeSpace News:As of 14:45 on March 6, 2026, the CSI All-Sector Medical Device Index (H30217) surged 2.01%. Among its constituent stocks, Hualan Group rose 10.28%, Zhongyuan Union Stem Cell Bio-Engineering gained 10.00%, and Guanhao Biotech advanced 5.88%. Sino Medical Sciences Technology, Valiant Medical and other individual stocks followed the upward trend. TheMaxwealth CSI All Share Medical Apparatus And Instruments ETF(159883) rose 1.84% to a latest price of RMB 0.5. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

In terms of liquidity, theMaxwealth CSI All Share Medical Apparatus And Instruments ETFposted an intraday turnover rate of 2.68% with a trading volume of RMB 170 million. Over a longer timeframe, as of March 5, its average daily trading volume reached RMB 202 million in the past week, ranking first among comparable funds.

In terms of scale, the ETF has achieved a significant growth with a scale increase of RMB 4.409 billion in the past year, and its newly added scale ranks 1st among 4 comparable funds. (Data source: Wind)

In terms of shares, the ETF has realized a remarkable growth with a share increase of 4.291 billion in the past three months, and its newly added shares rank 2nd among 4 comparable funds. (Data source: Wind)

Data showed that leveraged funds have been continuously building positions in the ETF. The latest margin purchase volume of theMaxwealth CSI All Share Medical Apparatus And Instruments ETFreached RMB 14.7347 million, with the latest margin balance standing at RMB 247 million. (Data source: Wind)

In terms of profitability, as of March 5, 2026, since its establishment, the ETF has achieved a maximum monthly return of 22.97%, a longest streak of four consecutive monthly gains with a cumulative increase of 19.79% during the period, and an average return of 4.57% in rising months. As of March 5, 2026, the ETF has an annualized excess return of 1.07% over the benchmark in the past two years, ranking top 2 among 4 comparable funds.

In terms of drawdown, as of March 5, 2026, the ETF has a relative benchmark drawdown of 0.12% since the start of the year.

In terms of fees, the ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%, which is at a relatively low level among comparable funds.

In terms of tracking accuracy, as of March 5, 2026, the ETF has a tracking error of 0.024% in the past two years, ranking the highest in tracking accuracy among comparable funds.

Notably, the CSI All-Sector Medical Device Index tracked by the ETF is at a historically low valuation level, with the latest price-to-book ratio (PB) standing at 2.94 times, lower than that in more than 84.38% of the time in the past three years, reflecting outstanding valuation cost performance.

TheMaxwealth CSI All Share Medical Apparatus And Instruments ETFclosely tracks the CSI All-Sector Medical Device Index. To reflect the overall performance of listed company securities in different industries within the CSI All-Sector Index sample and provide analytical tools for investors, the CSI All-Sector Index sample is classified into 11 first-tier industries, 35 second-tier industries, more than 90 third-tier industries and over 200 fourth-tier industries according to the CSI industry classification. Indices are then compiled with all securities in each of the first, second, third and fourth-tier industries as samples, forming the CSI All-Sector Industry Index Series.

Data showed that as of February 27, 2026, the top 10 weight stocks of the CSI All-Sector Medical Device Index (H30217) were Mindray Medical, United Imaging Healthcare, Lepu Medical, Yuyue Medical, Amic Technology, Huitai Medical, New Industries Biomedical Engineering, Intco Medical, Furui Medical and Rayence Technology, accounting for a total of 43.42% of the index weight. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

LeadLeo Research Institute stated that the AI medical device industry leverages artificial intelligence technology for medical purposes based on medical device data. The industry boasts a wide range of application fields and a diverse mix of market entrants, with the number of approved Class III medical device certificates growing steadily. Its market scale has expanded year by year, benefiting from the commercialization of artificial intelligence technology, policy-driven development, and the gradual penetration of AI medical devices into medical institutions and third-party imaging centers.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.